Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -30.00p -0.53% 5,610.00p 5,560.00p 5,660.00p 5,680.00p 5,540.00p 5,660.00p 9,072 16:11:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 175.0 -38.3 16.2 389.8 3,408.08

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
11/1/201809:11(Chi-Med)Hutchinson China Meditech Limited1,248
13/6/201706:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-01-18 16:12:075,560.0025013,900.00O
2018-01-18 16:03:255,640.00532,989.20O
2018-01-18 15:45:225,600.002,000112,000.00O
2018-01-18 15:35:285,640.00351,974.00O
2018-01-18 15:28:035,640.00412,312.40O
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 5,640p.
Hutchison China Meditech has a 4 week average price of 4,702.50p and a 12 week average price of 4,230p.
The 1 year high share price is 5,920p while the 1 year low share price is currently 2,085p.
There are currently 60,750,132 shares in issue and the average daily traded volume is 12,518 shares. The market capitalisation of Hutchison China Meditech is £3,408,082,405.20.
reptile3: I don't want to lower the tone of the thread which is exemplary in my opinion but does anyone have any idea what effect Chinese government approval of the licence would have on the share price?
nerdofsteel: miti - good call, we also have Eli Lilly's last chance to decide if they want to take up global rights to Fruquintinib, and if they do they'll have to make a big lump sum payment which will radicalley alter our 2018 numbers. This will be a $20bn mcap company in the next 5 years IMO My 2017 share price target of £52ish has been trounced completely! My 2018 calendar year end proce target is £61 but there's every chance that could be hit in January.....clearly I need to re-visit my valuationm model....£250 by 2026
reptile3: At 3:53 UK time share price on NASDAQ = $39.86. Times 2 = $79.72 which equals £59.30. Another all time high. I agree that £100 next year looks very possible. A happy, healthy and prosperous new year to all.
nerdofsteel: in the meantime, a nice quiet time, no dramas, hopefully a period of share price stability for a while eg. no more rises for a while would be welcome
reptile3: Nerdofsteel..... yes the share price is driven by the Americans and delisting from AIM at some point might be logical but from a purely selfish point of view I would prefer not to lose my ISA protection. Perhaps the way forward would be to wait until the market cap. is higher and transfer to the main London market. This would attract the index trackers at least.
mad foetus: Amazing that nobody notices this company - incredible share price record, incredible prospects, massive positive response to fund raising, share price sharply up and nobody notices. LOL!
steeplejack: Hutchison Healthcare Holdings Limited ("HHHL"), Chi-Med's majority shareholder holding approximately 60.36% of Chi-Med's share capital, has given a non-binding indication of interest to purchase up to US$182.0 million in ADSs in the aggregate in the Offering on the same terms as other investors. In addition,they may issue additional equity depending on demand taking the total issue to around $300m.Explains recent weakening of share price.
nerdofsteel: The number of watchers, and the correpsonding number of posts on Stocktwits (one of the main U.S. Retail Investor Bulletin Boards) has incerased dramatically in the last week, coupled with yesterday's large volumes. Positions being taken......... As I said on post 1018, you only have to look at the fiarly accurately forecast revs and EBITDA numbers to see where we will be, bearing in mind the U.S. market are in contyrol of the share price, and unlike the UK market, the U.S completely get how to value Biotechs, as they effectively invented the process and the nPV formulas. Also worth looking at HCM's track record over the last 10 years and you will see what they've delivered. The Directors keep buying for a simple reason............they know where this is going in trhe medium to lonmg term but don't care much about the short term - after all, they are in the drug development business One more thing to note - the CEO said at the time of the interims that they were working on 2 or 3 things, any one of which would DRAMATICALLY change 2017 guidance Look at the deal Beigene has done with Celgene and you will see the potential deal
nerdofsteel: "What price would you advise buying at?" Any, I mean the share price has grown in excess of 2000% in the last 10 years and we don't have a drug on the market, yet, although our first application has been submitted to the CFDA, so expect launch next year, followed by a number of others. If you look at a P/S of say 14 and a P/E of say 70 (Genmab is a great peer to compare HCM to) you can see Analysts forecasting sales of circa $650m by 2020 which equates to $9,100m mcap or circa £108 per share ish. So if anyone has a long term view like me (8 - 10 yrs) this is a bargain, even at this price IMO
nerdofsteel: "The relative ignorance in the US about the company’s potential makes it a great investment right now" This article offers a great perspective for those looking to invest for the long term, and by that I mean 5 years + And it is the U.S share price that mainly drives the UK share price now, as volumes are usually bigger on NASDAQ
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180119 01:57:39